Baxter International (BAX) has announced the launch of its next-generation airway clearance system, the Vest Advanced Pulmonary Experience (APX) System. This innovative device is designed to support daily therapy for both adults and children suffering from specific chronic lung conditions and issues with retained secretions. Earlier this year, the Vest APX System received clearance from the Food and Drug Administration (FDA) under the 510(k) program.
Jim O'Connell, President of Front Line Care at Baxter, remarked, "The Vest APX System provides enhanced comfort, user-friendliness, and portability, all while maintaining the reliable performance that patients and caregivers have trusted for years."
